Diagnostic and prognostic value of circulating exosomal glypican-1 in pancreatic cancer: a meta-analysis.

Laboratory medicine Pub Date : 2024-09-04 DOI:10.1093/labmed/lmae013

Zengyun Qiao, Enbo Wang, Boyang Bao, Xiaodong Tan, Hailong Chen, Dong Wang, Liu Yuan

{"title":"Diagnostic and prognostic value of circulating exosomal glypican-1 in pancreatic cancer: a meta-analysis.","authors":"Zengyun Qiao, Enbo Wang, Boyang Bao, Xiaodong Tan, Hailong Chen, Dong Wang, Liu Yuan","doi":"10.1093/labmed/lmae013","DOIUrl":null,"url":null,"abstract":"Background: Pancreatic cancer (PC) is usually detected in the advanced stages. Liquid biopsy has become a revolutionary strategy for cancer diagnosis and prognosis prediction. This study aims to investigate the diagnostic and prognostic value of circulating exosomal glypican-1 (GPC-1) in PC.Methods: We systematically searched relevant studies. For diagnostic accuracy, pooled sensitivity and specificity and the area under the summary receiver operating characteristic curve (AUC) were calculated. Regarding prognostic value, hazard ratios (HRs) and 95% CIs for overall survival (OS) were summarized by using a random-effects model.Results: We found 8 studies that examined the diagnostic value of circulating exosomal GPC-1 in PC, and 3 studies that investigated its prognostic value. Pooled sensitivity and specificity were 0.88 (95% CI, 0.65-0.97) and 0.86 (95% CI, 0.72-0.94). The AUC was 0.93 (95% CI, 0.90-0.95). Prognostic analysis showed that higher levels of circulating exosomal GPC-1 were associated with poorer OS in PC patients, and the combined HR for OS was 4.59 (random-effects model, 95% CI = 1.17-18.03, P = .022). The results of both studies were robust and neither had publication bias.Conclusion: Circulating exosomal GPC-1 may be used as a diagnostic and prognostic biomarker for PC. However, this result needs to be validated by further research using a larger sample size.","PeriodicalId":94124,"journal":{"name":"Laboratory medicine","volume":" ","pages":"543-552"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/labmed/lmae013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Pancreatic cancer (PC) is usually detected in the advanced stages. Liquid biopsy has become a revolutionary strategy for cancer diagnosis and prognosis prediction. This study aims to investigate the diagnostic and prognostic value of circulating exosomal glypican-1 (GPC-1) in PC.

Methods: We systematically searched relevant studies. For diagnostic accuracy, pooled sensitivity and specificity and the area under the summary receiver operating characteristic curve (AUC) were calculated. Regarding prognostic value, hazard ratios (HRs) and 95% CIs for overall survival (OS) were summarized by using a random-effects model.

Results: We found 8 studies that examined the diagnostic value of circulating exosomal GPC-1 in PC, and 3 studies that investigated its prognostic value. Pooled sensitivity and specificity were 0.88 (95% CI, 0.65-0.97) and 0.86 (95% CI, 0.72-0.94). The AUC was 0.93 (95% CI, 0.90-0.95). Prognostic analysis showed that higher levels of circulating exosomal GPC-1 were associated with poorer OS in PC patients, and the combined HR for OS was 4.59 (random-effects model, 95% CI = 1.17-18.03, P = .022). The results of both studies were robust and neither had publication bias.

Conclusion: Circulating exosomal GPC-1 may be used as a diagnostic and prognostic biomarker for PC. However, this result needs to be validated by further research using a larger sample size.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

循环外泌体 glypican-1 在胰腺癌中的诊断和预后价值：一项荟萃分析。

背景：胰腺癌（PC）通常在晚期才被发现。液体活检已成为癌症诊断和预后预测的革命性策略。本研究旨在探讨循环外泌体glypican-1（GPC-1）在PC中的诊断和预后价值：方法：我们系统检索了相关研究。方法：我们系统地检索了相关研究，计算了诊断准确性、汇总灵敏度和特异性以及汇总接收者操作特征曲线下面积（AUC）。关于预后价值，采用随机效应模型总结了总生存率（OS）的危险比（HRs）和 95% CIs：我们发现有 8 项研究探讨了循环外泌体 GPC-1 在 PC 中的诊断价值，有 3 项研究探讨了其预后价值。汇总的敏感性和特异性分别为 0.88（95% CI，0.65-0.97）和 0.86（95% CI，0.72-0.94）。AUC为0.93（95% CI，0.90-0.95）。预后分析表明，循环外泌体GPC-1水平越高，PC患者的OS越差，OS的综合HR为4.59（随机效应模型，95% CI = 1.17-18.03，P = .022）。这两项研究的结果都很可靠，而且都没有发表偏倚：结论：循环外泌体GPC-1可作为PC的诊断和预后生物标志物。然而，这一结果还需要通过更大样本量的进一步研究来验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Laboratory medicine

自引率

0.00%

发文量